Cargando…
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypot...
Autores principales: | Cooper, Jason P., Storer, Barry E., Granot, Noa, Gyurkocza, Boglarka, Sorror, Mohamed L., Chauncey, Thomas R., Shizuru, Judith, Franke, Georg-Nikolaus, Maris, Michael B., Boyer, Michael, Bruno, Benedetto, Sahebi, Firoozeh, Langston, Amelia A., Hari, Parameswaran, Agura, Edward D., Petersen, Søren Lykke, Maziarz, Richard T., Bethge, Wolfgang, Asch, Julie, Gutman, Jonathan A., Olesen, Gitte, Yeager, Andrew M., Hübel, Kai, Hogan, William J., Maloney, David G., Mielcarek, Marco, Martin, Paul J., Flowers, Mary E. D., Georges, George E., Woolfrey, Ann E., Deeg, H. Joachim, Scott, Bart L., McDonald, George B., Storb, Rainer, Sandmaier, Brenda M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168504/ https://www.ncbi.nlm.nih.gov/pubmed/32499241 http://dx.doi.org/10.3324/haematol.2020.248187 |
Ejemplares similares
-
Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014) -
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019) -
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019) -
Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms
por: Monaco, Federico, et al.
Publicado: (2019) -
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
por: Bensinger, W, et al.
Publicado: (2012)